Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价重组溶瘤腺病毒注射剂(KD01)瘤内给药在晚期实体瘤患者中的安全性和耐受性的单臂、多中心的I期临床研究
[Translation] A single-arm, multicenter phase I clinical study to evaluate the safety and tolerability of intratumoral administration of a recombinant oncolytic adenovirus injection (KD01) in patients with advanced solid tumors
评估KD01瘤内给药在晚期实体瘤患者人群中的安全性和耐受性,并探索其在人体中的最大耐受剂量(MTD)或II期临床推荐剂量(RP2D)。
[Translation] To evaluate the safety and tolerability of intratumoral administration of KD01 in patients with advanced solid tumors and explore its maximum tolerated dose (MTD) or recommended dose for Phase II clinical trials (RP2D) in humans.
100 Clinical Results associated with Wuhan Kaidejinuo Biotechnology Co., Ltd.
0 Patents (Medical) associated with Wuhan Kaidejinuo Biotechnology Co., Ltd.
100 Deals associated with Wuhan Kaidejinuo Biotechnology Co., Ltd.
100 Translational Medicine associated with Wuhan Kaidejinuo Biotechnology Co., Ltd.